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Abstract     Fibrates have been reported to elevate the hepatic proportion of oleic acid 
(18:1n-9) through inducing stearoyl-CoA desaturase (SCD). Despite abundant studies on the 
regulation of SCD in the liver, little is known about this issue in the small intestine. The 
present study aimed to investigate the effect of clofibric acid on the fatty acid profile, 
particularly MUFA, and the SCD expression in intestinal mucosa. Treatment of rats with a 
diet containing 0.5 % (w/w) clofibric acid for 7 days changed the MUFA profile of total lipids 
in intestinal mucosa; the proportion of 18:1n-9 was significantly increased, whereas those of 
palmitoleic (16:1n-7) and cis-vaccenic (18:1n-7) acids were not changed. Upon the treatment 
with clofibric acid, SCD was induced and the gene expression of SCD1, SCD2 and fatty acid 
elongase (Elovl) 6 was up-regulated, but that of Elovl5 was unaffected. Fat-free diet feeding 
for 28 days increased the proportions of 16:1n-7 and 18:1n-7, but did not effectively change 
that of 18:1n-9, in intestinal mucosa. Fat-free diet feeding up-regulated the gene expression of 
SCD1, but not that of SCD2, Elovl6 or Elovl5. These results indicate that intestinal mucosa 
significantly changes its MUFA profile in response to challenges by clofibric acid and a 
fat-free diet and suggest that up-regulation of the gene expression of SCD along with Elovl6 
is indispensable to elevate the proportion of 18:1n-9 in intestinal mucosa. 
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Abbreviations 
Acox  Peroxisomal acyl-CoA oxidase 
ATP  Adenosine triphosphate 
BSA  Bovine serum albumin 
ChREBP Carbohydrate responsive element-binding protein 
Clofibric acid 2-(4-Chlorophenoxy)-2-methylpropionic acid  
EDTA  Ethylenediaminetetraacetic acid 
Elovl  Fatty acid elongase 
ER  Endoplasmic reticulum 
Fads  Fatty acid desaturase 
NADH  Nicotinamide adenine dinucleotide 
PCR  Polymerase chain reaction 
PPARα  Peroxisome proliferator-activated receptor α 
SCD  Stearoyl-CoA desaturase  
SREBP-1c Sterol regulatory element-binding protein-1c 
TAG          Triacylglycerol 
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Introduction 
Stearoyl- CoA desaturase (SCD) is located in the endoplasmic reticulum (ER) membrane, and 
is involved in the de novo synthesis of monounsaturated fatty acids (MUFAs) from saturated 
fatty acids [1-3]. The major products of SCD are palmitoleoyl-CoA and oleoyl-CoA, which 
are formed by the desaturation of palmitoyl-CoA and stearoyl-CoA, respectively. Highly 
homologous isoforms of SCD have been shown to exist. Four isoforms of SCD (SCD1 to 
SCD4) have been identified in mice [4, 5], whereas two isoforms (SCD1 and SCD2) have 
been characterized in rats [6]. With regard to the regulation of SCD expression, hepatic SCD 
has been the most extensively studied; the activity and expression of hepatic SCD are affected 
by hormonal, nutritional, pathophysiological or pharmacological alterations [7]. 
2-(4-Chlorophenoxy)-2-methylpropionic acid (clofibric acid) is one of the fibrates, 
which lower triacylglycerol (TAG) and raise high-density lipoprotein in circulation. These 
beneficial effects were confirmed by several clinical trials, such as the Veterans Affairs 
High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) study [8] and Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study [9]. The finding of peroxisome 
proliferator-activated receptor α (PPARα) has helped understand mechanism behind the 
pharmacological action of fibrates. Fibrates have been demonstrated to exert its 
antiatherogenic effects on macrophages, smooth muscle cells, endothelial cells and leukocytes 
in artery wall through the activation of PPARα [10]. Moreover, fibrates augment the level of 
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high-density lipoprotein through the control of expression of aoplipoproteins A-I, A-II and 
A-IV. Triacylglycerol (TAG)-lowering effect of fibrates is generally considered to be 
attributable to suppression of apolipoprotein C-III expression and induction of lipoprotein 
lipase expression through the activation of PPARα [11]. In addition to beneficial effects of 
fibrates on lipoprotein metabolism, however, Karahashi et al. showed that fibrates up-regulate 
adipose triglyceride lipase along with fatty acid transporters and β-oxidation enzymes in the 
liver [12], suggesting the possibility that fibrates alleviate hepatic steatosis and 
hypertriglyceridemia. On the one hand, previous studies have revealed that clofibric acid has 
different modes of effects on fatty acid metabolism in the liver [12-15]. Namely, the drug has 
abilities to induce many enzymes related to fatty acid modification (desaturation and chain 
elongation) [13-15]. The administration of clofibric acid to rats increased the mass proportion 
of octadecenoic acid in hepatic lipids [13]. To elucidate the physiological significance of this 
observation, a series of studies were performed and demonstrated that the administration of 
clofibric acid to rats induced SCD in the liver [13, 14] and that the induction of SCD by 
clofibric acid is due to elevation of the expression of SCD1 through the activation of PPARα 
[15, 16] and to the suppression of the degradation of SCD [16]. Thus, accelerated formation 
of oleic acid (18:1n-9) by inducing SCD in the liver of rats is considered to be one of the 
pharmacological effects of clofibric acid [17]. In a recent study, fibrates were shown to 
elevate the gene expression of SCD1 and SCD2 in the liver of rats [18]. Since SCD controls 
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formation of MUFAs and there is increasing evidence suggesting that 18:1n-9, palmitoleic 
(16:1n-7) and cis-vaccenic (18:1n-7) acids have individually distinct physiological 
significance [19-21], it is important to understand the regulation of MUFA profile in 
extrahepatic organs. However, different from the detailed studies on the regulation of SCD in 
the liver, little information is available about the effects of fibrates on SCD expression in 
extrahepatic tissues.  
The small intestine is an organ for the absorption of nutrients and plays a central role in 
whole body lipid homeostasis. Most studies on the fatty acid metabolism in this organ have 
been focused on the uptake of fatty acids into mucosal cells from the lumen, their 
esterification to complex lipids and the subsequent formation of chylomicrons. On the other 
hand, little is known about the modification of fatty acids within this organ. Since the small 
intestine is the organ that is most susceptible to orally administered drugs, SCD expression in 
this organ is expected to be strongly influenced by the oral administration of fibrates. To our 
knowledge, however, the regulation of SCD by fibrates in intestinal mucosa has not been 
reported. The aim of this study is thus to clarify the effects of clofibric acid on the gene 
expression and enzyme activity of SCD and the subsequent change of the MUFA profile in 
the intestinal mucosa of rats. 
 
Materials and Methods 
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 Materials   
 
 [1-14C] Stearic acid (18:0) (55 Ci/mol) was purchased from American Radiolabeled 
Chemicals, Inc (St. Louis, MO, USA). Clofibric acid, stearic acid and bovine serum albumin 
(BSA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibody against SCD1 
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). NADH and CoA 
were purchased from Oriental Yeast Co. (Tokyo, Japan). Glutathione, polyoxyethylene (20) 
sorbitan monolaurate (Tween-20), polyoxyethylene (20) sorbitan monostearate (Tween-60) 
and peroxidase-conjugated secondary antibody were from Wako Pure Chemical (Osaka, 
Japan). ECL Prime Western Blotting Detection System was purchased from GE Healthcare 
(Chalfont St. Giles, UK). All other chemicals used were of analytical grade. 
 
Animals and Treatments 
 
All animal procedures were approved by Josai University’s Institutional Animal Care 
Committee in accordance with the Guidelines for Proper Conduct of Animal Experiments 
(Science Council of Japan). Five-week-old male Wistar rats were obtained from SLC 
(Hamamatsu, Japan). Animals were fed a standard diet (CE-2; Clea Japan Inc., Tokyo, Japan) 
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ad libitum and allowed free access to water. The fatty acid composition (in mol %) of the 
standard diet was as follows: palmitic acid (16:0), 23.2 %; 16:1n-7, 2.0 %; 18:0, 2.4 %; 
18:1n-9, 19.7 %; 18:1n-7, 2.2 %; linoleic acid (18:2n-6), 42.1 %; α-linolenic acid (18:3n-3), 
3.6 %; arachidonic acid (20:4n-6), 0.2 %; 5,8,11,14,17-eicosapentaenoic acid (20:5n-3), 
2.9 %; 7,10,13,16,19-docosapentaenoic acid (22:5n-3), 0.3 %; and 
4,7,10,13,16,19-docosahexaenoic acid (22:6n-3), 1.3 %. After acclimatization for 1 week, the 
rats were divided into three groups. Group1 was fed a standard diet (CE-2) for 28 days; 
Group2 was fed a diet (CE-2) admixed with 0.5 % (w/w) clofibric acid for 7 days before 
sacrifice; Group3 was fed a fat-free diet for 28 days. The fat-free diet (fat-deprived AIN-93G) 
was purchased from Oriental Yeast (Tokyo, Japan) and contained (by weight): 46.7486 % 
cornstarch, 20.0000 % casein, 13.2000 % dextrinized cornstarch, 10.0000 % sucrose, 
5.0000 % cellulose, 3.5000 % mineral mix AIN 93G, 1.0000 % vitamin mix AIN 93G, 
0.3000 % L-cysteine, 0.2500 % choline bitartrate and 0.0014 % tetra-butylhydroquinone. The 
treatments (dose and period) with clofibric acid are known to cause conditions that effectively 
induce PPARα-mediated enzymes and proteins such as SCD [18], peroxisomal acyl-CoA 
oxidase [22-24], 1-acylglycerophosphocholine acyltransferase [22-24] and fatty acid-binding 
protein [25] in the liver, kidney or intestinal mucosa without any signs of untoward response. 
At the age of 10 weeks, under diethyl ether anesthesia, rats were killed and the small intestine 
was excised. After washing with ice-cold saline, the mucosa was scraped off. One part of the 
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intestinal mucosa was frozen in liquid nitrogen and stored at -80 °C for the determination of 
mRNA and fatty acids. The other part of the mucosa was used for preparing microsomes. 
After centrifugation at 800 × g for 5 min at 0 °C, collected mucosa was homogenized with 6 
volumes of 0.25 M sucrose/1 mM ethylenediaminetetraacetic acid (EDTA)/10 mM Tris-HCl 
(pH 7.4) in a Potter glass-Teflon homogenizer. The homogenates were centrifuged at 10,000 × 
g for 20 min and supernatant was centrifuged at 105,000 × g for 60 min. The obtained pellet 
was resuspended in 0.25 M sucrose/0.1 mM EDTA/10 mM Tris-HCl (pH 7.4) and 
recentrifuged under the same conditions. The resulting pellets were resuspended in a small 
volume of 0.25 M sucrose/0.1 mM EDTA/10 mM Tris-HCl (pH 7.4). The suspension was 
frozen in liquid nitrogen and stored at -80 °C. The concentrations of protein were determined 
by the method of Lowry et al. [26] with BSA as a standard. 
 
Fatty Acid Analyses 
 
Total lipid was extracted from intestinal mucosa by the method of Bligh and Dyer [27], after 
the addition of nonadecanoic acid as an internal standard. The extracted lipids were saponified 
with 10 % methanolic KOH for 60 min at 80 °C under a nitrogen atmosphere. After removal 
of non-saponified materials with n-hexane three times, samples were acidified with 6 M HCl 
and free fatty acids were extracted with n-hexane three times. The extracts were heated with 
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15 % boron trifluoride in methanol at 100 °C for 10 min under a nitrogen atmosphere. All 
solvents employed for lipid analyses contained 0.005 % (w/v) butylated hydroxytoluene. The 
composition of the fatty acid methyl esters was determined by gas-liquid chromatography 
(Shimadzu GC-2014; Shimadzu, Kyoto, Japan), equipped with a flame-ionization detector 
using a fused silica capillary column (SLB-IL100, 30 m × 0.32 mm internal diameter, film 
thickness 0.26 μm) (Sigma-Aldrich) with helium gas as a carrier gas. Initial column 
temperature was 120 °C for 5 min, which was thereafter increased by 3 °C per min to a final 
temperature of 230 °C. The injection port temperature was 240 °C and a flame-ionization 
detector was used at 240 °C. 
 
mRNA Expression 
 
Total RNA was prepared from the intestinal mucosa using QIAzol reagent and RNeasy kit 
(QIAGEN, Hilden, Germany). cDNA was synthesized from 500 ng of total RNA with avian 
myeloblastosis virus reverse transcriptase (Takara, Shiga, Japan). Real-time polymerase chain 
reaction (PCR) experiments were carried out using SYBR premix ExTaq (Takara). The 
amplification and detection were performed with Step One plus real-time PCR system (Life 
Technologies Corp., Carlsbad, CA, USA). The thermal cycling program was as follows: 10 
sec denaturation step at 95 °C, followed by 50 cycles of 5 sec denaturation at 95 °C, and 34 
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sec annealing and extension at 60 °C. After the reaction, dissociation curve analyses were 
carried out to confirm the amplification of a single PCR product. Changes in gene expression 
were calculated by using the comparative threshold cycle (Ct) method. Ct values were first 
normalized by subtracting the Ct value obtained from β-actin (control). The sequences of 
primers used in this study are listed in Table 1. 
 
Immunoblot Analyses  
  
Microsomes (50 μg of protein) were separated by sodium dodecylsulfate/polyacrylamide gel 
electrophoresis on a 10 % gel and then transferred to a polyvinylidene difluoride membrane 
(BioRad, Hercules, CA, USA) using a Trans-Blot Semi-Dry Electrophoretic Transfer Cell 
(BioRad). The membrane was blocked in Tris-buffered saline (pH 7.6) containing 0.1 % 
Tween-20, 5 % skim milk and 1 % BSA for 60 min, and then incubated with primary 
antibodies (1:1000) overnight. After washing with Tris-buffered saline (pH 7.6) containing 
0.1 % Tween-20, the membrane was incubated with horseradish peroxidase-conjugated 
secondary antibodies (1:5000) for 60 min in Tris-buffered saline (pH 7.6) containing 0.1 % 
Tween-20, 5 % skim milk and 1 % BSA. After washing three times in Tris-buffered saline 
(pH 7.6) containing 0.1 % Tween-20, proteins were visualized using the ECL Prime reagent 
(GE Healthcare) and detected in a luminoimage analyzer, LAS-1000 (GE Healthcare).  
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 Stearoyl-CoA Desaturase Assay   
 
The stearoyl-CoA desaturation activity was measured essentially according to the method of 
Catalá [28] with some modifications. [1-14C]18:0 and 18:0 dissolved in toluene were mixed, 
and the solution was taken to dryness under a stream of nitrogen. To the residue was added 
0.1 M NH4OH, and the solution was vortex-mixed to obtain a uniform milky suspension, as 
described by Ullman and Sprecher [29]. The [1-14C]stearic acid solution was then diluted to a 
concentration of 250 nmol (0.5 μCi)/0.1 mL by the addition of a solution of 1 % Tween-60 in 
water. The reaction mixture contained 100 nmol [1-14C] 18:0 (0.2 μCi), 0.4 μmol NADH, 0.1 
μmol CoA, 4 μmol ATP, 4 μmol MgCl2, 1.5 μmol glutathione, 1 mg of microsomal protein 
and 100 mM potassium phosphate buffer (pH 7.4) in a total volume of 0.5 mL. Incubation 
was performed at 37 °C for 20 min, and the reaction was stopped by adding 2 mL of 10 % 
methanolic KOH, followed by saponification at 85 °C for 60 min. After acidification with 6 
M HCl, fatty acids were extracted with n-hexane three times, and methyl esters were prepared 
by heating at 100 °C for 10 min with boron trifluoride in methanol. The methyl esters were 
extracted with n-hexane and subjected to argentation-thin-layer chromatography in order to 
separate the monounsaturated from the saturated fatty acids. Silica gel G plates 
(0.25-mm-thick) (Merck, Darmstadt, Germany) were immersed in 15 % (w/v) AgNO3 in 
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acetonitrile and then air-dried. The plate was heated at 115 °C for 120 min for activation 
before use. Plates were developed in n-hexane/diethyl ether (9:1, by vol.). The spots were 
visualized under ultraviolet light after spraying with 0.05 % (w/v) Rhodamine B in 95 % 
ethanol. The areas corresponding to authentic methyl stearate and methyl oleate were scraped 
off the plates, and methyl esters were extracted with toluene and then mixed with 
toluene-based scintillator. The radioactivity was measured using a liquid scintillation counter 
(Aloka LS-5100; Hitachi Aloka Medical Ltd., Tokyo, Japan). 
 
Statistical Analyses   
 
Homogeneity of variance was established using one-way analysis of variance. When a 
difference was significant (p < 0.05), Scheffé’s multiple range test was used as a post hoc test. 
The statistical significance of the difference between two means was evaluated by Student’s t- 
test or Welch’s test after the F-test.  
 
Results 
 
Effects of Clofibric Acid on MUFA Profile of Lipids of Intestinal Mucosa   
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Table 2 shows the effects of clofibric acid on the fatty acid profile of total lipids of intestinal 
mucosa. By the treatment of rats with clofibric acid for 7 days, the proportion of 18:1n-9 was 
significantly increased to 148 % of that of the control. In contrast, the proportions of 16:1n-7 
and 18:1n-7 were not significantly changed. Figure 1a shows the difference in mass (nmol/mg 
protein) of particular fatty acids between the two groups of rats. Among the MUFAs, the 
content of 18:1n-9 was significantly increased by treatment with clofibric acid. There were no 
considerable differences in the masses of 16:1n-7 and 18:1n-7 between control and clofibric 
acid-treated rats. Ratio 18:0/16:0 tended to be increased (0.72 vs. 0.87) by the treatment with 
clofibric acid. 
 
Effects of Clofibric Acid on SCD Expression in Intestinal Mucosa 
 
The effects of clofibric acid on the protein expression and activity of SCD in microsomes of 
intestinal mucosa were estimated (Fig. 2). SCD protein was measured by western blot 
analysis; SCD activity was determined using [14C] 18:0 as a substrate. The treatment of rats 
with clofibric acid increased the protein level of SCD1 in microsomes by 2.1-fold (Fig. 2a). 
SCD activity in microsomes of intestinal mucosa was also elevated 2.4-fold by the 
administration of clofibric acid (Fig. 2b). To gain insight into the molecular basis of the effect 
of clofibric acid on the MUFA profile, the mRNA levels of key enzymes involved in the 
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metabolism of fatty acid modification were measured (Fig. 3). With regard to the expression 
of genes encoding SCD, the mRNA levels of SCD1 and 2 in the intestinal mucosa of the rats 
that were treated with clofibric acid were 24-fold and 8.2-fold, respectively, higher than those 
of the control. In addition, the mRNA level of fatty acid elongase (Elovl) 6 was 5.7-fold 
up-regulated by the treatment with clofibric acid, whereas the expression of Elovl5 was 
unchanged.  
 
Effects of Clofibric Acid on Polyunsaturated Fatty Acid (PUFA) Profile in Intestinal Mucosa 
 
As shown in Table 2, treatment of rats with clofibric acid increased the proportions of 8,11, 
14-eicosatrienoic acid (20:3n-6) (212 %) and 5, 8, 11-eicosatrienoic acid (20:3n-9) (222 %)  
in total lipids of intestinal mucosa. On the other hand, the proportion of 18:2n-6 was 
decreased to about 83 % of the control by the treatment with clofibric acid. Figure 1a shows 
the increase in mass of 20:3n-6 and the decreases in those of 18:2n-6 and 20:4n-6. As a result, 
ratio of 20:3n-6 to 20:4n-6 was increased 2.4-fold by the treatment with clofibric acid. The 
mRNA levels of Δ6 fatty acid desaturase (Fads2) and Δ5 fatty acid desaturase (Fads1) were 
significantly increased by 7.9-fold and 5.8-fold, respectively, by the treatments of rats with 
clofibric acid (Fig. 3). 
 
15 
 
Comparison of Effects of Clofibric Acid with those of Fat-free Diet on Fatty Acid Profile in 
Intestinal Mucosa 
 
Table 2 shows the effects of clofibric acid and fat-free diet feeding on the profile of fatty acid 
of total lipids in intestinal mucosa. The treatment of rats with fat-free diet for 28 days 
significantly increased the proportions of 16:1n-7 (450 %) and 18:1n-7 (238 %). In particular, 
the increase in mass of 16:1n-7 was the most significant and was 84 nmol/mg protein by fat 
deprivation from the diet (Table 2; Fig. 1b). Although clofibric acid treatment increased the 
proportion of 18:1n-9, fat-free diet feeding did not significantly change the proportion of 
18:1n-9. Fat-free diet feeding caused a significant decrease in the proportion of 18:2n-6 (54 % 
of the control), whereas the proportion of 20:3n-9 was significantly increased by 4.2-fold. The 
effects of fat-free diet on gene expression of the enzymes involved in fatty acid modification 
were determined (Fig. 4). The mRNA level of SCD1 was increased by 3.6-fold, while that of 
SCD2 tended to increase, but not significantly. The gene expression of Elovl5, Elovl6, Fads1 
and Fads2 was not significantly altered by feeding on the fat-free diet.  
 
Effects of Clofibric Acid and Fat-free Diet on Expression of Nuclear Transcription Factors 
 
As shown in Table 3, the administration of clofibric acid to rats increased the mRNA level of 
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acyl-CoA oxidase 1 (Acox1) by 3.5-fold and that of PPARα by 3.3-fold. The treatment of rats 
with clofibric acid also elevated the level of mRNA encoding sterol regulatory 
element-binding protein-1c (SREBP-1c) by 3.8-fold, whereas the mRNA level of 
carbohydrate regulatory element-binding protein (ChREBP) was lower (61 %) than that of the 
control. In contrast, fat-free diet feeding did not significantly affect the mRNA levels of 
PPARα, SREBP-1c, ChREBP and Acox1.  
 
Discussion 
 
Previous studies demonstrated that the treatment of rodents with fibrates markedly induced 
SCD activity, thereby increasing 18:1n-9 content in the liver [13-17]. However, the regulation 
of SCD in extrahepatic tissues, in particular the small intestine, has not been well investigated, 
and little is known about whether fibrates affect the MUFA profile in intestinal mucosa. 
Treatments with fibrates are known to affect the expression of various genes in the small 
intestine, such as Niemann-Pick C1-like 1 (NPCL1L) [30], uncoupling protein 2 (UCP2) [31], 
Acox1 [24, 32] and adipocyte triglyceride lipase [33], which are related to lipid metabolism. 
Fibrates alter TAG metabolism in enterocytes by increasing fatty acid oxidation [34, 35]. Our 
previous studies demonstrated that clofibric acid treatment of rats induced 
1-acylglycerophosphocholine acyltransferase and fatty acid-binding protein in intestinal 
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mucosa [24, 36]. These findings, taken together, strongly suggest that the small intestine is 
susceptible to fibrates with regard to MUFA metabolism. As anticipated, the present results 
demonstrated that the treatment of rats with clofibric acid caused an increase in the proportion 
of 18:1n-9 in intestinal mucosa of rats. It seemed likely that the augmentation of the 
proportion and mass of 18:1n-9 was attributable to the induction of SCD1 and SCD2 along 
with Elovl6. On the other hand, the proportions of 16:1n-7 and 18:1n-7 were largely 
unchanged, in contrast to the pronounced rise in SCD expression. It is unclear why the 
proportions of 16:1n-7 and 18:1n-7 in the lipids were not significantly changed, in spite of the 
elevation of SCD activity in intestinal mucosa, by clofibric acid treatment. It is interesting to 
speculate that Elovl6, which was up-regulated by clofibric acid, actively elongated 16:0 to 
18:0, and the increasingly formed 18:0 seemed to be desaturated to 18:1n-9 by the induced 
SCD. As a result, the pathway of 16:0 → 16:1n-7 → 18:1n-7 seemed to be overwhelmed by 
that of 16:0 → 18:0 → 18:1n-9 (Fig. 5). The conclusion that Elovl6 along with SCD1 plays a 
crucial role in the regulation of 18:1n-9 formation is the same as that of Karahashi et al. [37] 
and Marks et al. [38], who showed the role of Elovl6 in the liver of Goto-Kakizaki rats and 
female rats, respectively. 
     Previous studies demonstrated that fat-free diet feeding resulted in the up-regulation of 
SCD1 mRNA [39] and in the increase in the proportions of 16:1n-7 and 18:1n-9 in the liver 
[40]. Therefore, we attempted to compare the effect of clofibric acid treatment with that of 
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fat-free diet feeding on MUFA synthesis in intestinal mucosa. In contrast to the case of 
clofibric acid treatment, fat deprivation from the diet caused striking elevation of the 
proportions of 16:1n-7 and 18:1n-7, but not 18:1n-9, in the lipid of intestinal mucosa by the 
significant increase in expression of the SCD1 gene. It should be noted that the expression of 
Elovl6 was unchanged by feeding on a fat-free diet. It seems likely that the increased 
proportions of 16:1n-7 and 18:1n-7 were due to the predominant conversion of 16:0 to 
16:1n-7, which was efficiently elongated to 18:1n-7 in the intestinal mucosa of rats fed a 
fat-free diet (Fig. 5). 
The inducing effects of fibrates on SCD and Elovl are considered to be attributable to 
their actions as synthetic ligands for PPARα [41]; most of these conclusions are derived from 
experiments using knockout mice or cultured cells. PPARs are nuclear hormone receptors that 
function as transcriptional regulators of key metabolic pathways [42]. Our previous studies 
showed that treatment with clofibric acid elevated mRNA levels of SCD1, SCD2 and Elovl6 
in the liver of rats [16, 18]. The present study evidently showed that the treatment of rats with 
clofibric acid augmented the expression of the PPARα gene and of genes encoding SCD1, 
SCD2, Elovl6 and Acox1 in intestinal mucosa. Acox1 is a typical gene of which the 
expression is up-regulated by peroxisome proliferators and this induction has been 
demonstrated to be mediated through the activation of PPARα [43]. Accordingly, the present 
results suggest that the increase in Acox1 gene expression by clofibric acid indicates that 
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PPARα was activated by the drug in intestinal mucosa. Thus, the clofibric acid-induced gene 
expression of SCD1, SCD2 and Elovl6 in the intestinal mucosa is likely to be mediated by 
PPARα, as reported in the liver. In addition to PPARα, the expression of SCD and Eovl6 is 
known to be regulated by SREBP-1c and ChREBP [44]. The present study showed that the 
treatment of rats with clofibric acid significantly increased expression of the SREBP-1c gene 
in intestinal mucosa. SREBP-1c is thought to be another regulator of SCD [45, 46], and the 
presence of PPARα has been shown to be required for proper functioning of SREBP-1c [47]. 
Overexpression of ChREBP in the liver leads to the induction of SCD1 and specific increases 
in the proportions of 16:1n-7 and 18:1n-9 [48]; in the present study, however, the treatment 
with clofibric acid significantly decreased the gene expression of ChREBP in intestinal 
mucosa. Consequently, it is the most likely that PPARα plays a central role in the regulation 
of the MUFA profile under the influence of clofibric acid in intestinal mucosa as well as 
hepatocytes. Different from the case of clofibric acid, fat-free diet feeding did not affect the 
expression of genes for PPARα, SREBP-1c and ChREBP in intestinal mucosa. However, the 
detailed mechanism for inductions of SCD1 by fat-free diet remains unclear. 
The present study shows that the treatment of rats with clofibric acid considerably 
changed the PUFA profile in lipids of intestinal mucosa. The proportions of 20:3n-6, but not 
20:4n-6, was significantly increased, while that of 18:2n-6 was evidently decreased, by the 
treatment. The process of 20:4n-6 formation requires Δ6 desaturation of 18:2n-6 to 18:3n-6, 
20 
 
chain elongation of 18:3n-6 to 20:3n-6 and Δ5 desaturation of 20:3n-6 to 20:4n-6. Metabolic 
alterations in this process have been extensively studied in the liver [4, 5], whereas less 
information is available on PUFA biosynthesis in intestinal mucosa. An early study by Garg 
et al. demonstrated that the rat small intestine also possesses Δ6-desaturase activity [49]. 
Moreover, Christiansen et al. showed that the activity of chain elongation of 18:3n-6 to 
20:3n-6 in the small intestine is comparable to that in the liver [50]. The present study 
revealed that the treatment of rats with clofibric acid induced the expression of Fads2 (Δ6 
desaturase) and Fads1 (Δ5 desaturase) in intestinal mucosa. Similarly, the rate of 20:4n-6 
formation from 18:2n-6 has been reported to be increased in the liver of rats and mice treated 
with fibrates [51, 52]. Since a previous study demonstrated dual regulation of Fads1 and 
Fads2 gene expression by PPARα and SREBP-1c in the liver of mice [53], a similar 
mechanism is likely to operate for induction of the expression of these genes in intestinal 
mucosa. The up-regulation of Fads2 by clofibric acid may elevate the proportion of 20:3n-6 in 
lipids of intestinal mucosa (Fig. 6). Although the cause of unchanged proportion of 20:4n-6, 
despite the increase in mRNA level of Fads1, by clofibric acid still remains to be elucidated, 
ratio 20:3n-6/20:4n-6 was significantly altered. Eicosanoids are proposed as mediators 
involved in the regulation of epithelial structure and function [54]. Since 20:3n-6 and 20:4n-6 
are precursors of eicosanoids, it is likely that alteration of the PUFA profile by clofibric acid 
in intestinal mucosa affects pathophysiological state of the small intestine. On the other hand, 
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fat-free diet feeding did not alter the expression of Fads1 and Fads2. Consequently, the levels 
of both 20:3n-6 and 20:4n-6 were not changed in intestinal mucosa (Fig. 6). Fat-free diet 
feeding caused an evident increase in 20:3n-9 content in intestinal mucosa. An increase in the 
mass of 20:3n-9 is generally observed in the liver of rodents when formation of 18:1n-9 is 
markedly increased, which is a condition found upon starved refeeding or the administration 
of PPARα agonist [55, 56]. The detailed mechanism involved in the elevation of 20:3n-9 
proportion in intestinal mucosa has not been clarified. 
A number of studies have demonstrated that the intestinal mucosa produces mucus 
phosphatidylcholine, lipid components of chylomicrons and phospholipids of 
cellular/organelle membranes utilizing fatty acids that originate from dietary fat. On the other 
hand, little is known about how extent the fatty acids that are produced endogenously by 
enterocytes themselves contribute to these processes. Of the fatty acids that could be provided 
by enterocytes themselves, 18:1n-9, 16:1n-7 and 18:1n-7 are of particularly interest, because 
recent evidence suggests that these MUFAs have individually distinct physiological 
significance. Namely, different from 18:1n-9, 16:1n-7 has been identified as an adipose 
tissue-derived lipid hormone capable of enhancing muscle insulin sensitivity [19], and 
18:1n-7 is suggested to be linked to chronic kidney disease [21] and to gluconeogenesis [20]. 
These MUFAs seem to be delivered from the small intestine to various organs through 
circulation as the components of chylomicrons. Moreover, a saturation grade of fatty acid 
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residues in the mucus phosphatidylcholine was increased in patients with ulcerative colitis 
[57]. Interestingly, phosphatidylcholine, indispensable to the maintenance of an intact barrier 
function, in mucus in the intestine including colon originate from secretion by ileal and 
jejunal enterocytes [58]. These facts, taken together, imply the importance of modification 
(desaturation and elongation) of fatty acids in enterocytes of the ileum and jejunum, whereas 
little is known about the modification of fatty acids in the small intestine. The present study 
clearly showed that fatty acid modification system in the small intestine sensitively responds 
to clofibric acid and dietary alterations, so that MUFA profile significantly changed. It seems 
likely that the altered MUFA profile is reflected to fatty acid profile of mucus 
phosphatidylcholine and to that of other organs through the secretion of chylomicrons. 
Therefore, it is interesting to suggest that the small intestine could be one of the targets to 
manipulate fatty acid profile of mucus phosphatidylcholine in the intestine and to regulate 
MUFA profile on whole body level. 
Finally, treatments of rats with clofibric acid elevated the proportion of 18:1n-9, but not 
that of either 16:1n-7 or 18:1n-7, and fat-free diet feeding increased the proportions of 
16:1n-7 and 18:1n-7, but not that of 18:1n-9. SCD1 is markedly induced by clofibric acid or a 
fat-free diet in intestinal mucosa; moreover, clofibric acid, but not a fat-free diet, up-regulated 
the expression of Elovl6. Therefore, it seems likely that elevation of the gene expression of 
SCD1 along with Elovl6 is indispensable for the increases in mass and proportion of 18:1n-9. 
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This conclusion is the same as that from previous studies on 18:1n-9 formation in the liver of 
Goto-Kakizaki rats [37] and female rats [38]. 
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Figure Legends 
 
Fig. 1  Difference in mass (nmol/mg protein) of fatty acids in total lipids of intestinal 
mucosa (a) between control rats and rats treated with clofibric acid, and (b) between control 
rats and rats fed on a fat-free diet. Rats were fed on a standard diet, a diet containing 0.5 % 
(w/w) clofibric acid for 7 days or a fat-free diet for 28 days. With regard to each fatty acid, 
differences in mass (nmol/mg protein) between the means of control rats and those of rats 
treated with clofibric acid or rats fed on a fat-free diet were calculated from the data in Table 2. 
Values are mean ± SD for 4 rats. Cont, control rats; Clo, clofibric acid-treated rats; Fat-free, 
rats fed a fat-free diet. 
 
Fig. 2  Effects of clofibric acid on protein levels (a) and enzyme activities (b) of SCD in 
microsomes of intestinal mucosa of rats. Rats were fed on a standard diet or a diet containing 
0.5 % (w/w) clofibric acid for 7 days. (a) The proteins (50 μg) of intestinal microsomes were 
separated by electrophoresis. Visible bands are SCD1, as indicated. Immunoblotting was 
carried out with anti-SCD1 antibody. (b) SCD activity in microsomes of intestinal mucosa 
was measured using [14C] 18:0 as a substrate. Values are mean ± SD for 4 rats. Cont, control 
rats; Clo, clofibric acid-treated rats. Significantly different from the control, **p < 0.01. 
 
Fig. 3  Effects of clofibric acid on levels of mRNA encoding enzymes involved in fatty acid 
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modification in intestinal mucosa of rats. Rats were fed on a standard diet or a diet containing 
0.5 % (w/w) clofibric acid for 7 days. The gene expression levels were analyzed by real-time 
PCR. Values are mean ± SD for 6-12 rats. Cont, control rats; Clo, clofibric acid-treated rats. 
Significantly different from the control, *p < 0.05, **p < 0.01. 
 
Fig. 4  Effect of fat-free diet feeding on levels of mRNA encoding enzymes involved in fatty 
acid modification in intestinal mucosa of rats. Rats were fed on a standard diet or a fat-free 
diet for 28 days. The gene expression levels were analyzed by real-time PCR. Values are 
mean ± SD for 4 rats. Cont, control rats; FF, fat-free diet-fed rats. Significantly different from 
the control, *p < 0.05.  
 
Fig. 5  Diagram of enzymes regulating the synthesis of 16:1n-7, 18:1n-7 and 18:1n-9 
 
Fig. 6  Diagram of enzymes regulating the synthesis of 20:3n-6 and 20:4n-6 
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Table 1   Sequences of primers used for real-time PCR 
  Primer sequence  (5’-3’)        Accession No. 
SCD1 F : TCACCTTGAGAGAAGAATTAGCA  J02585 
R : TTCCCATTCCCTTCACTCTGA 
SCD2 F : TGCACCCCCAGACACTTGTAA AB032243 
R : GGATGCATGGAAACGCCATA 
Fads1 F : TACAGGCAACCTGCAACGTTC    NM_053445 
R : GGTGCCACCTTGTGGTAGTTGT 
Fads2 F : GCCACTTAAAGGGTGCCTCC BC081776 
R : TGCAGGCTCTTTATGTCGGG 
Elovl5 F : ACCACCATGCCACTATGCTCA AB071985 
R : GGACGTGGATGAAGCTGTTG 
Elovl6 F : AGAACACGTAGCGACTCCGAA AB071986 
R : CAAACGCGTAAGCCCAGAAT 
Acox1 F : TTCGTGCAGCCAGATTGGTAG NM_017340 
R : CGGCTTTGTCTTGAATCTTGG 
PPARα F : AATGCCCTCGAACTGGATGAC NM_013196 
R : CACAATCCCCTCCTGCAACTT 
SREBP-1c F : GGAGCCATGGATTGCACATT AF286469 
R : AGGAAGGCTTCCAGAGAGGA 
ChREBP F : AATAGAGGAGCTCAATGCT AB074517 
R : CCCAGAACTTCCAGTTGTGC 
β-actin    F : TGCAGAAGGAGATTACTGCC V01217 
R : CGCAGCTCAGTAACAGTCC 
 
 Table 2  Effects of clofibric acid and fat free diet on fatty acid profile (mol%) of lipid of 
intestinal mucosa  
Fatty acids Control Clofibric acid Fat-free 
16:0 24.41 ± 1.65 22.17 ± 1.98 24.49 ± 1.43 
16:1n-7 1.43 ± 0.19a 1.77 ± 0.35a  6.43 ± 0.56b 
18:0 17.55 ± 1.81 19.22 ± 0.55  18.54 ± 0.86 
18:1n-9 11.80 ± 1.66a 17.51 ± 2.12b 15.52 ± 1.59ab 
18:1n-7 2.85 ± 0.08a 2.60 ± 0.24a 6.79 ± 0.36b 
18:2n-6 25.77 ± 1.08a 21.51 ± 1.49b 13.81 ± 1.18c 
18:3n-3 0.83 ± 0.11a 0.34 ± 0.16b 0.47 ± 0.04b 
20:3n-9 0.37 ± 0.05a 0.82 ± 0.11b 1.54 ± 0.18c 
20:3n-6 0.96 ± 0.22a 2.04 ± 0.09b 0.74 ± 0.10a 
20:4n-6 10.66 ± 1.26 9.35 ± 1.26  9.65 ± 2.90 
20:5n-3 1.36 ± 0.22a 1.51 ± 0.17a 0.74 ± 0.18b 
22:5n-3 0.92 ± 0.11a 0.68 ± 0.18ab 0.55 ± 0.22b 
22:6n-3 1.11 ± 0.17a 0.49 ± 0.06b 0.76 ± 0.37ab 
Total (nmol/mg protein) 1689.1 ± 176.4 1490.3 ± 103.6 1887.4 ± 441.5 
 
Rats were fed on a control diet, a diet containing 0.5 % (w/w) clofibric acid for 7 days or a 
fat-free diet for 28 days. Values represent mean ± SD for four rats. Differences in horizontal 
means without a common superscript (a, b, c) are significant (p < 0.05). In the absence of 
superscripts, differences in means are not significant ( p > 0.05). 
 
 
  
Table 3  Effects of clofibric acid and fat-free diet on gene expression of nuclear transcription 
factors in intestine of rats  
 
 Genes Control Clofibric acid Fat-free 
Acox1 1.00 ± 0.21a 3.53 ± 0.71b 0.79 ± 0.16a 
PPARα 1.00 ± 0.20a 3.25 ± 0.56b 0.55 ± 0.22a 
SREBP-1c 1.00 ±  0.39a 3.81 ± 1.17b 0.61 ± 0.16a 
ChREBP 1.00 ± 0.40a 0.61 ± 0.24ab 1.40 ± 0.67ac 
 
Rats were fed on a control diet or a diet containing 0.5 % (w/w) clofibric acid for 7 days or a 
fat-free diet for 28 days. Values represent mean ± SD for 4-12 rats. Differences in horizontal 
means without a common superscript (a, b, c) are significant (p < 0.05). In the absence of 
superscripts, differences in means are not significant ( p > 0.05). 
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